The third Food and Drug Administration decision in three days is scheduled for tomorrow, when the agency is scheduled to decide on the fate of Chelsea Therapeutics’ (NAS: CHTP) Northera, a treatment for neurogenic orthostatic hypotension, or NOH. The advisory panel recommended approval of the drug by a margin of 7-4, with one panelist abstaining and another deciding not to vote at all. Despite the positive recommendation, clearly the panel wasn’t gung-ho about approving the drug, which will weigh on the agency that was already questioning the safety profile before the meeting.
